Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model.
Open Access
- 1 December 1993
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 92 (6), 2994-3002
- https://doi.org/10.1172/jci116922
Abstract
Current organ preservation strategies subject graft vasculature to severe hypoxia (PO2 approximately 20 Torr), potentially compromising vascular function and limiting successful transplantation. Previous work has shown that cAMP modulates endothelial cell (EC) antithrombogenicity, barrier function, and leukocyte/EC interactions, and that hypoxia suppresses EC cAMP levels. To explore the possible benefits of cAMP analogs/agonists in organ preservation, we used a rat heterotopic cardiac transplant model; dibutyryl cAMP added to preservation solutions was associated with a time- and dose-dependent increase in the duration of cold storage associated with successful graft function. Preservation was also enhanced by 8-bromo-cAMP, the Sp isomer of adenosine 3',5'monophosphorothioate, and types III (indolidan) and IV (rolipram) phosphodiesterase inhibitors. Neither butyrate alone nor 8-bromoadenosine were effective, and the cAMP-dependent protein kinase antagonist Rp isomer of adenosine 3',5'monophosphorothioate prevented preservation enhancement induced by 8-bromo-cAMP. Grafts stored with dibutyryl cAMP demonstrated a 5.5-fold increase in blood flow and a 3.2-fold decreased neutrophil infiltration after transplantation. To explore the role of cAMP in another cell type critical for vascular homeostasis, vascular smooth muscle cells were subjected to hypoxia, causing a time-dependent decline in cAMP levels. Although adenylate cyclase activity was unchanged, diminished oxygen tensions were associated with enhanced phosphodiesterase activity (59 and 30% increase in soluble types III and IV activity, respectively). These data suggest that hypoxia or graft ischemia disrupt vascular homeostasis, at least in part, by perturbing the cAMP second messenger pathway. Supplementation of this pathway provides a new approach for enhancing cardiac preservation, promoting myocardial function, and maintaining vascular homeostatic properties.This publication has 64 references indexed in Scilit:
- Inhibition of Granulocyte cAMP-Phosphodiesterase by Rolipram In Vivo Is Not Sufficient to Protect the Canine Myocardium from Reperfusion InjuryJournal of Cardiovascular Pharmacology, 1992
- University of Wisconsin solution for human donor heart preservation: Initial clinical experienceThe Annals of Thoracic Surgery, 1991
- IMPROVEMENT IN EXPERIMENTAL CARDIAC PRESERVATION BASED ON METABOLIC CONSIDERATIONSTransplantation, 1991
- Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion.Journal of Clinical Investigation, 1991
- Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogsJournal of Medicinal Chemistry, 1989
- Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.Stroke, 1989
- Free Radicals in Hypothermic Rat Heart Preservation — Prevention of Damage by Mannitol and DesferrioxamineFree Radical Research Communications, 1987
- Leukocytes and Ischemia-Induced Myocardial InjuryAnnual Review of Pharmacology and Toxicology, 1986
- Diastereomers of adenosine 3′,5′‐monothionophosphate (cAMP[S] antagonize the activation of cGMP‐dependent protein kinaseEuropean Journal of Biochemistry, 1985
- Diminished Polymorphonuclear Leukocyte AdherenceJournal of Clinical Investigation, 1980